Clinical Trial Update: A Phase I Study of gp100 Human Melanoma Peptide Vaccine With Incomplete Freund's Adjuvant [Phase 1]

View source ↗

Summary

Phase I study of the gp100 melanoma peptide vaccine with incomplete Freund's adjuvant has completed, reporting safety and immunogenicity data in melanoma patien…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Incomplete Freund's adjuvant (Incomplete Freund's adjuvant)
• gp100 melanoma peptide vaccine (gp100 melanoma peptide vaccine)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Melanoma | Phase 1 | Status: COMPLETED